Why Aditxt Shares Are Rallying Today?
February 2, 2024
CNBC
Aditxt Inc's (NASDAQ: ADTX ) therapeutic program Adimune has completed a toxicology study indicating a favorable safety profile of ADI-100 for rejection of transplanted organs, skin allografting, autoimmune diseases, and allergies.
The company says the completion of preclinical toxicity study of ADI-100, potentially a psoriasis drug candidate advances it closer to human ... Full story available on Benzinga.com
SweepCast
Simplest Unusual Options Activity Platform for traders. SweepCast can be used for swing or day traders who are looking to get insights on where Smart money is flowing, sign up today.